Berrio, IndiraCaceres, Diego H.Coronell R, WilfridoSalcedo, SorayaMora, LauraMarin, AdrianaVarón, CarmenLockhart, Shawn R.Escandón, PatriciaBerkow, Elizabeth L.Rivera, SandraChiller, TomVallabhaneni, Snigdha2020-05-212020-05-21202020487207https://hdl.handle.net/20.500.12442/5708Background. Candida auris is an emerging multidrug-resistant yeast that can cause invasive infections and healthcareassociated outbreaks. Here, we describe 34 cases of pediatric C. auris bloodstream infections (BSIs) identified during July 2014– October 2017 in 2 hospitals in Colombia. Methods. We conducted a retrospective review of microbiology records for possible C. auris cases in 2 hospitals in Barranquilla and Cartagena. BSIs that occurred in patients aged <18 years confirmed as C. auris were included in this analysis. Results. We identified 34 children with C. auris BSIs. Twenty-two (65%) patients were male, 21% were aged <28 days, 47% were aged 29–365 days, and 32% were aged >1 year. Underlying conditions included preterm birth (26%), being malnourished (59%), cancer (12%), solid-organ transplant (3%), and renal disease (3%). Eighty-two percent had a central venous catheter (CVC), 82% were on respiratory support, 56% received total parenteral nutrition (TPN), 15% had a surgical procedure, and 9% received hemodialysis. Preinfection inpatient stay was 22 days (interquartile range, 19–33 days), and in-hospital mortality was 41%. Conclusions. Candida auris affects children with a variety of medical conditions including prematurity and malignancy, as well as children with CVCs and those who receive TPN. Mortality was high, with nearly half of patients dying before discharge. However, unlike most other Candida species, C. auris can be transmitted in healthcare settings, as suggested by the close clustering of cases in time at each of the hospitals.pdfengAttribution-NonCommercial-NoDerivatives 4.0 InternacionalBloodstream infectionsCandida aurisChildrenarticleinfo:eu-repo/semantics/restrictedAccesshttps://doi.org/10.1093/jpids/piaa038